30th European Hematology Association Congress
(EHA 2025)
Fueled by Connections to Transform Rare Diseases
Agios at EHA 2025
New data on Agios’ pyruvate kinase (PK) activators, mitapivat and tebapivat, will be featured in oral and poster presentations highlighting their potential across serious conditions with limited or no current treatment options, including sickle cell disease, thalassemia, pyruvate kinase deficiency, and myelodysplastic syndromes.
In total, 14 presentations and publications led by Agios and external collaborators will be shared at EHA 2025.
Visit the company’s booth (#C04) onsite.
Agios EHA 2025 Data Room & Resources
Agios EHA 2025 Data Room
View Agios- and collaborator-led presentations and publications shared at EHA 2025.
Medical & Scientific Resources
Access educational and scientific resources related to Agios’ investigational and approved medicines. This site is for healthcare professionals only.
PYRUKYND® (mitapivat)
Learn more about Agios’ FDA-approved PK activator. This site is for U.S. healthcare professionals only.
Rethink Thalassemia
Find out more about the subtypes of thalassemia, its risks and complications and how to manage the disease. This site is for U.S. healthcare professionals only.
Know PK Deficiency
Access information on PK deficiency and how to manage the disease, disease burden, and importance of management. This site is for U.S. healthcare professionals only.
6/25